Cosette intros generic MetroGel-Vaginal

Cosette Pharmaceuticals has received the green light from the Food and Drug Administration for a generic version of Bausch Health’s MetroGel-Vaginal (metronidazole vaginal gel 0.75%). This product will be launched immediately.

The medication is used to treat women with vaginal infections.

“We are thrilled at the approval and launch of an additional affordable alternative product, serving women’s health. This FDA approval is further validation of our stellar R&D, regulatory, manufacturing and commercial capabilities," said Apurva Saraf, president and CEO of Cosette Pharmaceuticals. "We will continue to deliver on our commitment to provide important, high-quality, affordable medicine for patients in women’s health care.”

[Read more: The women’s health category experiences disruption]

Metronidazole vaginal gel 0.75% had a market value of roughly $45 million for the 12 months ended December 2022, per IQVIA.

MetroGel and MetroGel-Vaginal are registered trademarks of Galderma Holdings S.A.

[Read more: Female surgeon creates revolutionary OTC product]